METHODS FOR TREATING NEUROLOGICAL DISORDERS
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A a...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English French |
Published |
15.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
La présente divulgation concerne des composés et des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent la kinase 1A régulée par la phosphorylation de la tyrosine à double spécificité (DYRK1A). Ces entités chimiques sont utiles, par exemple, pour traiter une affection, une maladie ou un trouble dans lesquels une activation accrue (par exemple, excessive) de la DYRK1A contribue à la pathologie et/ou aux symptômes et/ou à la progression de l'affection, de la maladie ou du trouble (par exemple, un cancer) chez un sujet (par exemple, un être humain). Cette divulgation concerne également des compositions contenant lesdites entités, ainsi que des procédés d'utilisation et de fabrication de celles-ci. |
---|---|
Bibliography: | Application Number: WO2022US52453 |